When did 10x Genomics, Inc. report Q2 2025 earnings?

10x Genomics, Inc. (TXG) reported Q2 2025 earnings on August 7, 2025 after market close.

What were 10x Genomics, Inc.'s Q2 2025 revenue and EPS?

10x Genomics, Inc. reported revenue of $172.9M and eps of $0.28 for Q2 2025.

Did 10x Genomics, Inc. beat estimates in Q2 2025?

Revenue beat the consensus estimate of $139.5M by $33.4M. EPS beat the consensus estimate of $-0.35 by $0.63.

How did 10x Genomics, Inc.'s Q2 2025 results compare year-over-year?

Compared to the same quarter a year prior, revenue grew 12.9% from $153.1M a year earlier.

Where can I find 10x Genomics, Inc.'s Q2 2025 SEC filings?

You can read the 10-Q periodic report (0001770787-25-000051) directly on SEC EDGAR. The filing index links above go to sec.gov.

10x Genomics, Inc. TXG Q2 2025 earnings

Reported August 7, 2025 · After market close

Revenue$172.9MBeat by $33.4M

EPS$0.28Beat by $0.63

Revenue estimate$139.5M

EPS estimate-$0.35

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$146.7M

EPS estimate-$0.23

Financials

Q2 2025

Income statement

See full

Revenue$172.9M+12.9%

Gross profit$125.1M+20.0%

Operating income$30.1M+172%

Net income$34.5M+191%

EPS (diluted)$0.28+188%

Balance sheet

See full

Cash & equivalents$397.7M+4.7%

Total debt$86.7M-3.1%

Total equity$773.3M+6.8%

Total assets$980.0M+5.4%

Cash flow

See full

Operating cash flow$17.7M—

CapEx$1.6M-45.2%

Free cash flow$16.1M—

Valuation & ratios

Valuation

as of 06/30/25

See full

Market cap$1.34B-42.3%

Enterprise value$1.03B-49.3%

P/S2.1×-1.6×

Profitability

See full

Gross margin69.5%+4.8pp

Operating margin-15.6%-5.9pp

Net margin-13.1%-5.2pp

FCF margin8.8%—

Returns & leverage

See full

Return on equity-11.3%-4.4pp

Debt / equity0.1×0.0×

Current ratio5.8×+0.6×

Segments

By product

See full

Products and services revenue$145.2M-5.1%

Chromium$85.8M-8.8%

License and royalty revenue$27.8M+24,243%

Spatial$8.8M-41.8%

Services$8.5M+46.7%

By geography

See full

Europe, Middle East and Africa$34.7M-7.0%

Asia-Pacific (excluding China)$8.8M-0.8%

Americas (excluding United States)$2.7M-22.0%

Versus estimates

Revenue

Q1 2026$150.8MBeat by $4.4M Q4 2025$166.0MBeat by $6.4M Q3 2025$149.0MBeat by $6.5M

Q2 2025$172.9MBeat by $33.4M

Q1 2025$154.9MBeat by $9.6M Q4 2024$165.0MIn line

Diluted EPS

Q1 2026-$0.10Beat by $0.19 Q4 2025-$0.13Beat by $0.06 Q3 2025-$0.22Miss by $0.15

Q2 2025$0.28Beat by $0.63

Q1 2025-$0.36Beat by $0.09 Q4 2024-$0.40Miss by $0.11

Ask the moment 10x Genomics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did 10x Genomics, Inc. report Q2 2025 earnings?: 10x Genomics, Inc. (TXG) reported Q2 2025 earnings on August 7, 2025 after market close.
What were 10x Genomics, Inc.'s Q2 2025 revenue and EPS?: 10x Genomics, Inc. reported revenue of $172.9M and eps of $0.28 for Q2 2025.
Did 10x Genomics, Inc. beat estimates in Q2 2025?: Revenue beat the consensus estimate of $139.5M by $33.4M. EPS beat the consensus estimate of $-0.35 by $0.63.
How did 10x Genomics, Inc.'s Q2 2025 results compare year-over-year?: Compared to the same quarter a year prior, revenue grew 12.9% from $153.1M a year earlier.
Where can I find 10x Genomics, Inc.'s Q2 2025 SEC filings?: You can read the 10-Q periodic report (0001770787-25-000051) directly on SEC EDGAR. The filing index links above go to sec.gov.